In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • Management of Novel Oral Anticoagulant-Associated Intracranial Hemorrhage

    Final Number:
    1684

    Authors:
    Aislyn DiRisio BS; Maya Harary; Ivo S Muskens BSc; Ismaeel Yunusa Pharm.D.; Sanvritti Manjekar BS; Thomas Simjian; William B. Gormley MD; Timothy R. Smith MD PhD MPH; Rania A Mekary PhD; Marike Broekman MD, PhD, JD

    Study Design:
    Other

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2017 Annual Meeting

    Introduction: Intracranial hemorrhage (ICH) is the most devastating complication of anticoagulant therapy. Randomized controlled trials have shown novel-oral anticoagulants (NOACs) to reduce the risk of ICH and ICH-related mortalities as compared to Vitamin K Antagonists. NOACs also act quickly and are not affected by diet. Nevertheless, there are no universally accepted recommendations for reversal, and no laboratory test that can reliably quantify the degree of anticoagulation on NOAC therapy exists.

    Methods: A systematic review of the literature was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Studies that reported strategies and/or outcomes regarding the management of NOAC-associated ICH were selected. Information was extracted on NOAC reversal strategies, anticoagulation resumption, ICH expansion, and ICH recurrence.

    Results: Our search yielded 4148 articles that discussed oral anticoagulation and intracranial hemorrhage. After screening articles, we identified 23 articles that discussed the management or outcomes of NOAC-associated ICH. Studies showed that the risk of recurrence and/or re-expansion was non-inferior to warfarin-associated ICH. Reversal strategies varied among institutions, and mostly included 4-factor prothrombin complex concentrate (PCC), 8-factor PCC, fresh frozen plasma (FFP), hemodialysis, packed red blood cells, and Idarucizimab. Only one study discussed strategies for resuming NOAC anticoagulation after ICH and found that 40% of patients resumed dabigatran at time of discharge.

    Conclusions: There are no standardized reversal and treatment regimens for NOAC-associated ICH. Several reversal strategies have been proposed in the literature. Nevertheless, the literature showed that outcomes after NOAC-associated ICH were non-inferior than outcomes after warfarin-associated ICH. Future studies are warranted to assess the efficacy of reversal strategies in improving outcomes for NOAC-associated ICH. Additionally, further research should focus on balancing continued risk of thromboembolism with the risk of recurrent hemorrhage to better guide decisions regarding the resumption of NOAC anticoagulation therapy following ICH.

    Patient Care: Though the reduced risk for ICH on NOACs as compared to warfarin is well known, less is known about the management strategies for reversal and reinitiation of NOACs after ICH. This research will give providers a comprehensive understanding of the literature on ICH management to better help these patients.

    Learning Objectives: 1. Review literature on risks and benefits associated with restarting NOACs after ICH 2. Understand relative effectiveness and associated risks of reversal strategies for NOAC-associated ICH 3. Understand how management strategies apply to different patient groups

    References:

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy